PMID- 32910500
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1478-3231 (Electronic)
IS  - 1478-3223 (Linking)
VI  - 40
IP  - 11
DP  - 2020 Nov
TI  - Proton pump inhibitors and odds of cholangiocarcinoma: A retrospective 
      case-control study.
PG  - 2848-2857
LID - 10.1111/liv.14663 [doi]
AB  - BACKGROUND & AIMS: Proton pump inhibitors (PPIs) have been reported to be 
      associated with cholangitis and might possibly be carcinogenic. However, few 
      studies have been conducted to investigate the association of PPIs with 
      cholangiocarcinoma (CCA). Thus, a hospital-based case-control study was carried 
      out in China to explore the association between PPIs and CCA. METHODS: In this 
      study, 1468 CCA cases (826 intrahepatic cholangiocarcinoma (ICC) and 642 
      extrahepatic cholangiocarcinoma (ECC)) were included, which were observed at 
      Beijing Friendship Hospital, from February 2002 to October 2018. We 
      retrospectively extracted PPI use and other possible risk factors from clinical 
      records, followed by an investigation of the relationship with CCA via 
      calculation of odds ratios (ORs), adjusted odds ratios (AORs), and 95% confidence 
      intervals (CIs) using logistic regression analysis. RESULTS: PPIs were used by 
      135 (9.2%) CCA cases and 173 (5.9%) controls. We found that PPI use was 
      associated with a 1.61-fold elevated CCA odds (P < .001) (AOR = 1.61, 95% 
      CI = 1.28-2.05; P < .001). After stratification by CCA subtypes, the AORs of PPIs 
      were consistent for both CCA subtypes, with ORs of 1.36 (AOR = 1.36, 95% 
      CI = 1.02-1.83; P = .003) and 1.95 (AOR = 1.95, 95% CI = 1.46-2.62; P < .001) for 
      ICC and ECC respectively. Our results also showed that PPI use was slightly 
      linked to the odds of CCA in a dose-dependent manner. CONCLUSION: PPI use was 
      correlated with a significant 61% increased odds of CCA, particularly in the ECC. 
      However, the retrospective design and observational nature cannot establish 
      causation. Larger scale, multi-centre prospective studies are required for 
      further validation.
CI  - (c) 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Xiong, Jianping
AU  - Xiong J
AUID- ORCID: 0000-0001-6593-6377
AD  - Department of Interventional Radiology, Beijing Friendship Hospital, Capital 
      Medical University, Beijing, China.
FAU - Wang, Yaqin
AU  - Wang Y
AD  - Department of Interventional Radiology, The First Affiliated Hospital of China 
      Medical University, Shenyang, China.
FAU - Xu, Weiyu
AU  - Xu W
AD  - Department of General Surgery, Beijing Friendship Hospital, Capital Medical 
      University, Beijing, China.
FAU - Liu, Zhisong
AU  - Liu Z
AD  - Faculty of Statistics, Tianjin University of Finance and Economics, Tianjin, 
      China.
FAU - Wang, Haochen
AU  - Wang H
AD  - Department of Interventional Radiology, Beijing Friendship Hospital, Capital 
      Medical University, Beijing, China.
FAU - Zhang, Zhiyuan
AU  - Zhang Z
AD  - Department of Interventional Radiology, Beijing Friendship Hospital, Capital 
      Medical University, Beijing, China.
FAU - Han, Yanjing
AU  - Han Y
AD  - Department of Interventional Radiology, Beijing Friendship Hospital, Capital 
      Medical University, Beijing, China.
FAU - Yin, Chao
AU  - Yin C
AD  - Department of Interventional Radiology, Beijing Friendship Hospital, Capital 
      Medical University, Beijing, China.
FAU - Cao, Shasha
AU  - Cao S
AD  - Department of Interventional Radiology, Beijing Friendship Hospital, Capital 
      Medical University, Beijing, China.
FAU - Yang, Zheran
AU  - Yang Z
AD  - Department of Interventional Radiology, Beijing Friendship Hospital, Capital 
      Medical University, Beijing, China.
FAU - Su, Tianhao
AU  - Su T
AD  - Department of Interventional Radiology, Beijing Friendship Hospital, Capital 
      Medical University, Beijing, China.
FAU - Wei, Jian
AU  - Wei J
AD  - Department of Interventional Radiology, Beijing Friendship Hospital, Capital 
      Medical University, Beijing, China.
FAU - Chen, Guang
AU  - Chen G
AD  - Department of Interventional Radiology, Beijing Friendship Hospital, Capital 
      Medical University, Beijing, China.
FAU - Jin, Long
AU  - Jin L
AD  - Department of Interventional Radiology, Beijing Friendship Hospital, Capital 
      Medical University, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Liver Int
JT  - Liver international : official journal of the International Association for the 
      Study of the Liver
JID - 101160857
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - *Bile Duct Neoplasms/chemically induced/epidemiology
MH  - Case-Control Studies
MH  - China/epidemiology
MH  - *Cholangiocarcinoma/chemically induced/epidemiology
MH  - Humans
MH  - Prospective Studies
MH  - Proton Pump Inhibitors/adverse effects
MH  - Retrospective Studies
MH  - Risk Factors
OTO - NOTNLM
OT  - case-control
OT  - cholangiocarcinoma
OT  - proton pump inhibitors
OT  - risk factors
EDAT- 2020/09/11 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/09/10 12:28
PHST- 2020/03/18 00:00 [received]
PHST- 2020/08/22 00:00 [revised]
PHST- 2020/08/29 00:00 [accepted]
PHST- 2020/09/11 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/09/10 12:28 [entrez]
AID - 10.1111/liv.14663 [doi]
PST - ppublish
SO  - Liver Int. 2020 Nov;40(11):2848-2857. doi: 10.1111/liv.14663.